Vaccine maker Novavax (NVAX) has sunk to a new low for the move down as fundamental analysts are publishing weaker ratings. President Biden's recent assessment of Covid has not helped, either.
More from Investing
These recently downgraded names are displaying both quantitative and technical deterioration.
These kind of names are in short supply in the current market.
With the possibility of a sale of MANU getting kicked around, it's game-on for owners of the shares.
Let's explore MLPs that can offer above-average distribution yields.